sorafenib has been researched along with defactinib in 2 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (defactinib) | Trials (defactinib) | Recent Studies (post-2010) (defactinib) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 41 | 5 | 41 |
Protein | Taxonomy | sorafenib (IC50) | defactinib (IC50) |
---|---|---|---|
Tyrosine-protein kinase JAK2 | Homo sapiens (human) | 0.0282 | |
High affinity nerve growth factor receptor | Homo sapiens (human) | 0.0413 | |
Non-receptor tyrosine-protein kinase TYK2 | Homo sapiens (human) | 0.129 | |
Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.2732 | |
Tyrosine-protein kinase JAK3 | Homo sapiens (human) | 0.1149 | |
Mitogen-activated protein kinase kinase kinase 9 | Homo sapiens (human) | 0.0753 | |
Focal adhesion kinase 1 | Homo sapiens (human) | 0.0014 | |
Protein-tyrosine kinase 2-beta | Homo sapiens (human) | 0.0293 | |
NT-3 growth factor receptor | Homo sapiens (human) | 0.0578 | |
BDNF/NT-3 growth factors receptor | Homo sapiens (human) | 0.0549 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
Cho, H; Choi, HG; Jeon, E; Kim, ND; Kim, S; Kim, Y; Kwon, NH; Lee, J; Moon, Y; Ryu, S; Shin, I; Sim, T; Song, C; Yoon, H | 1 |
2 other study(ies) available for sorafenib and defactinib
Article | Year |
---|---|
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Identification of Thieno[3,2-
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; fms-Like Tyrosine Kinase 3; Focal Adhesion Kinase 1; Humans; Mice, Inbred BALB C; Mice, Nude; Molecular Docking Simulation; Molecular Structure; Neoplasm Metastasis; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship; Thiophenes; Xenograft Model Antitumor Assays | 2021 |